TFEB
The transcription factor TFEB acts as a master on-off switch for autophagy and the production of new lysosomes in the cell — one of the best-characterized molecular nodes linking these two processes, studied as a potential target for interventions in aging.
Number of studies
2
Safety
High
Time to effects
Not applicable — this is a regulatory mechanism studied at the molecular and cellular level, not an intervention with a measurable time course in humans.
Who it's for
Table of contents
TL;DR
The transcription factor TFEB acts as a master on-off switch for autophagy and the production of new lysosomes in the cell — one of the best-characterized molecular nodes linking these two processes, studied as a potential target for interventions in aging.
- →Coordinates both the autophagy process and the production of new lysosomes at once, rather than regulating them separately
- →Studied as a potential therapeutic target in neurodegenerative diseases linked to the buildup of proteins that cannot be cleared
- →Serves as a molecular link connecting nutrient signaling (mTOR) with the entire cellular clean-up pathway
| Molecule type | A transcription factor from the MiT/TFE family |
|---|---|
| Research level | Moderate — strong mechanistic evidence from animal and cell models, no approved interventions in humans |
| Main function | Coordinated regulation of autophagy and lysosome biogenesis via CLEAR motifs in DNA |
| Key inhibitory regulator | The kinase mTOR (phosphorylates TFEB, blocking its activation) |
| Discovery | Work by Andrea Ballabio's team, 2009–2011 (Science) |
| Status | Research target, no approved pharmacological activators for humans |
Understand
Overview
TFEB (transcription factor EB) is a protein from the MiT/TFE family of transcription factors, recognized as the master regulator of autophagy and lysosome biogenesis — two processes that are tightly linked, since it is inside lysosomes that components engulfed by autophagosomes are ultimately degraded. When TFEB is active, it moves into the cell nucleus and switches on an entire network of genes responsible for building autophagosomes, generating new lysosomes, and producing the digestive enzymes that work inside these organelles.
The discovery of TFEB's role (groundbreaking work by Andrea Ballabio's team between 2009 and 2011) was an important step in understanding that autophagy and lysosomal function are not independent processes, but parts of a single, coordinated transcriptional program responding to nutrient availability. TFEB is now intensively studied in the context of neurodegenerative diseases (where the buildup of proteins and damaged organelles that cannot be cleared is a central problem) and cellular aging — as a potential 'control node' whose increased activity could theoretically improve the cell's clean-up capacity.
An important caveat: despite promising results in animal models and cell lines, there are currently no approved, safe pharmacological interventions that activate TFEB in humans for longevity purposes. This remains a purely research-stage topic — worth following given the mechanism's fundamental importance, but not currently offering practical applications beyond the laboratory.
Mechanism of action
TFEB's activity is controlled mainly by its location within the cell, rather than by the amount of the protein itself. When nutrients are abundant, the kinase mTOR (located on the lysosome surface) phosphorylates TFEB, keeping it inactive in the cytoplasm. Under cell starvation or other stress (e.g., lysosomal dysfunction), mTOR activity drops, TFEB loses its phosphorylation, moves into the cell nucleus, and binds to DNA sequences called CLEAR motifs (Coordinated Lysosomal Expression and Regulation), triggering transcription of dozens of autophagy-lysosomal genes at once.
The result is a coordinated response: the cell simultaneously increases its capacity to form autophagosomes, produces new lysosomes, and boosts their digestive capacity — rather than making isolated, scattered changes. This makes TFEB a natural 'control node' for the entire autophagy-lysosome pathway, not just a regulator of one of its components, which explains why it is so intensively studied as a potential therapeutic target in diseases linked to the accumulation of proteins and organelles that cannot be cleared.
Phosphorylation by mTOR
When nutrients are abundant, mTOR phosphorylates TFEB, keeping it inactive in the cytoplasm.
Loss of phosphorylation under stress
Cell starvation or lysosomal stress lowers mTOR activity, releasing TFEB.
Translocation to the nucleus
Released TFEB moves into the cell nucleus.
Activation of CLEAR genes
TFEB binds to CLEAR motifs in DNA and simultaneously activates autophagy and lysosome-biogenesis genes.
Evidence: moderate — based on 2 studies in this database.
Benefits
Common myths
MythThere are supplements that safely 'activate TFEB' in humans.
FactThere are currently no approved, clinically validated substances that activate TFEB in humans for longevity purposes — research into TFEB activators remains at the animal and cell-model stage.
MythTFEB regulates only autophagy.
FactTFEB is the master regulator of both autophagy and lysosome biogenesis — two processes it regulates simultaneously and in a coordinated way through the same CLEAR motifs in DNA.
Check your profile
Not sure which supplements actually make sense for you?
Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
Practice
Frequently asked questions
TFEB is a transcription factor that, once activated, moves into the cell nucleus and simultaneously switches on genes responsible for autophagy and for producing new lysosomes.
The kinase mTOR phosphorylates TFEB when nutrients are abundant, keeping it in an inactive form in the cytoplasm — a drop in mTOR activity (e.g., during starvation) releases TFEB.
There is currently no validated, safe method for deliberately activating TFEB pharmacologically in humans — research into TFEB activators remains at the preclinical stage.
Because it coordinates the clearance of misfolded proteins and damaged organelles, TFEB is studied as a potential therapeutic target in diseases such as Alzheimer's or Parkinson's, though mainly in animal models so far.
What to combine with
Good combinations
Autophagy — TFEB is the main transcription factor switching on the genes necessary for autophagy to proceed
Lysosomal Health — TFEB directly drives the biogenesis of new lysosomes, making it a central regulator of lysosomal health
Proteostasis — By regulating autophagy and lysosomes, TFEB influences one of the main degradative arms of the proteostasis network
Safety
Side effects & contraindications
Possible side effects
Contraindications
No significant contraindications at typical doses.
Is it worth taking?
Who it's for
- People interested in the molecular basis of autophagy and lysosomal function
- People wanting to understand how nutrient signaling (mTOR) connects to cellular clean-up processes
Not for
- No significant contraindications at typical doses.
Evidence
Worth knowing
TFEB binds to DNA sequences called CLEAR motifs, switching on dozens of autophagy-lysosomal genes at once.
TFEB's location (cytoplasm vs. cell nucleus), not its amount, determines whether it is active.
Studies
TFEB links autophagy to lysosomal biogenesis
Moderate evidenceSettembre C, Di Malta C, Polito VA, et al. · Science · 2011
A landmark paper showing that TFEB coordinates autophagosome formation, fusion with the lysosome, and substrate degradation through a single, coherent transcriptional program regulated by nutrient availability.
View studyA gene network regulating lysosomal biogenesis and function
Moderate evidenceSardiello M, Palmieri M, di Ronza A, et al. · Science · 2009
A paper identifying TFEB as the master regulator of a gene network responsible for lysosome biogenesis and function, foundational for the later link between TFEB and autophagy.
View studySources & bibliography
The PubMed identifiers in this knowledge base were checked against NCBI records (October 2026). If you spot an error in a source, please let us know via the contact form.
Compare with similar entries
About the authors of this entry
Author
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna studied molecular biology at the University of Warsaw, then spent eight years after her PhD in a lab researching the mechanisms of cellular aging and autophagy. She stumbled into science journalism almost by accident — frustrated by how easily her field's findings get oversimplified in the media, she started a blog explaining the biology of aging in plain language. That blog became the seed of VitMode. Today Anna oversees the entire editorial process, holding every piece to the same rigor her old lab demanded: primary sources, methodology checks, and honesty about the limits of the evidence. Outside work, she's a dedicated boulderer.
227 publications on this site
Medical review
dr Piotr ZielińskiEndocrinologist
Piotr has practiced endocrinology for more than fifteen years, mostly in male hormonal disorders and metabolic health. He joined VitMode as a scientific consultant because, as he jokes, he got tired of explaining the same testosterone questions at every appointment and decided to write the answers down properly, once. He reviews content on hormone therapy, supplement pharmacology and drug interactions, making sure articles never turn into encouragement to self-supplement in situations that genuinely need diagnostics and medical supervision. His professional motto — "evidence first, enthusiasm second" — has come up more than once with a patient who arrived with a supplement plan they found online.
297 publications on this site
Related entries
4.3Autophagy
An intracellular 'housekeeping' process that clears out damaged proteins and organelles, whose discovery earned a Nobel Prize — one of the key mechanisms studied in the context of slowing aging.
3.9Lysosomal Health
Lysosomes — the cell's 'recycling centers' — accumulate unprocessed waste and lose capacity with age, a pattern increasingly described as one of the fundamental, shared denominators of cellular aging and a potential target for future interventions.
4.1Proteostasis
A cell's ability to maintain balance between protein production, correct folding, and degradation — a network of mechanisms whose capacity declines with age and is studied as one of the fundamental pillars of cellular aging.
4.0Mitophagy
A selective form of autophagy in which the cell recognizes and removes specifically damaged, dysfunctional mitochondria — a mitochondrial quality-control mechanism whose efficiency declines with age and is studied in the context of neurodegenerative disease.
4.3Inflammaging
Chronic, low-grade, systemic inflammation that accompanies aging even without an active infection — a term coined in 2000 by Claudio Franceschi, today considered one of the fundamental mechanisms linking aging to age-related disease.
4.2Immunosenescence
The progressive, multi-directional remodeling of the immune system with age — not a simple 'weakening,' but a complex change that both lowers the ability to fight new threats and raises the baseline level of inflammation.
Related articles
PoradnikiIntermittent Fasting 16:8 or 5:2 — Which Eating Window Should You Choose
Intermittent fasting has spawned dozens of variants, but two protocols have dominated the public imagination: the daily, restricted 16:8 eating window and the cyclical, stronger calorie restriction of the 5:2 method. This guide compares both approaches based on real clinical trials, showing that the choice between them rarely comes down to which one is 'better' — and more often to which one you can actually stick with for longer than a few weeks.
September 3, 2026
PoradnikiSpermidine and Autophagy: What Animal Studies and Early Human Trials Actually Show
Spermidine is a natural polyamine present in every cell of our body, whose levels steadily decline with age. It's one of the few natural compounds with real, repeated mechanistic evidence of autophagy activation and a large observational study linking higher intake to lower mortality. But it's also a good example of how a promising result from a small human pilot trial (30 people) failed to hold up in a larger, better-designed trial (100 people) run by the same team. We take a close look at what each study actually showed, and where the limits of our current knowledge lie.
September 9, 2026
PoradnikiFisetin as a Senolytic: What the Mouse Study Showed and Where Human Research Stands Today
Fisetin is a flavonoid found in strawberries, apples, and onions that made longevity-media headlines in 2018 as the strongest of the studied natural senolytics — compounds that selectively clear senescent (aging) cells. The mouse result was genuinely strong: extended lifespan and reduced markers of aging across many tissues. The problem is that several years have passed since that study, and clinical trials in humans are still at the stage of pilot safety trials, not confirmed efficacy. We take a close look at what is actually known and what remains only a promising hypothesis.
September 9, 2026
PoradnikiQuercetin as a Senolytic: What the First Human Studies of the Dasatinib + Quercetin Combination Show
Quercetin, the same flavonoid we covered in an earlier article in the context of allergic rhinitis, plays an entirely different, far more experimental role in aging biology: as part of a combination with the oncology drug dasatinib (the "D+Q" protocol), studied as a senolytic — a substance that selectively clears senescent cells. This is the first pair of senolytic compounds for which real data have been published showing a reduction in senescent cells in humans, not just in animals. We take a close look at what these first clinical trials actually showed, what role quercetin itself actually plays in them, and where the limits of this evidence lie.
September 9, 2026
PoradnikiDasatinib and Quercetin (D+Q): Why an Oncology Drug Was Paired With a Flavonoid, and What It Actually Means
The D+Q protocol — dasatinib, an oncology drug used in chronic myeloid leukemia, combined with quercetin, a widely available flavonoid — is today's best-studied senolytic combination in humans. Our earlier articles on fisetin and on quercetin as senolytics covered the same pilot trials from a different angle. Here we focus on the question those pieces skipped: why dasatinib, a drug with real, non-trivial toxicity, became quercetin's partner, and what the 'hit-and-run' dosing logic behind the whole protocol actually means.
October 10, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.